Korea's Boryung Takes Hypertension Drug Kanarb Beyond Korea With Stendhal Deal
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Boryung Pharma signed a licensing agreement with Stendhal International, a Mexico-based company, to supply the South Korean company's angiotensin receptor blocker Kanarb (fimasartan) for $22.6 million, marking the first time Kanarb will be sold outside of Korea
You may also be interested in...
After Mexican Marketing Deal, Korea's Boryung Ventures Into Central And South America
SEOUL - Following a similar deal with Mexico-based Stendhal International in January, Boryung Pharmaceutical Co. said it is close to signing marketing agreements for its angiotensin receptor blocker Kanarb (fimasartan) in 12 other Central and South American countries
After Mexican Marketing Deal, Korea's Boryung Ventures Into Central And South America
SEOUL - Following a similar deal with Mexico-based Stendhal International in January, Boryung Pharmaceutical Co. said it is close to signing marketing agreements for its angiotensin receptor blocker Kanarb (fimasartan) in 12 other Central and South American countries
Korea's Boryung Pharma Seeking MNCs To Sell Hypertension Product Abroad
SEOUL - South Korea's Boryung Pharma is seeking multinational partners to out-license its angiotensin receptor blocker Kanarb (fimasartan) in the U.S. and Europe